$852 Million is the total value of Paradigm Biocapital Advisors LP's 23 reported holdings in Q4 2022. The portfolio turnover from Q3 2022 to Q4 2022 was 46.4% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| INCY | Buy | INCYTE CORP | $68,499,306 | +33.0% | 852,830 | +10.3% | 8.04% | +17.1% |
| BIIB | Buy | BIOGEN INC | $66,120,742 | +60.2% | 238,772 | +54.4% | 7.76% | +41.1% |
| MRTX | Buy | MIRATI THERAPEUTICS INC | $57,451,721 | -3.3% | 1,267,970 | +49.1% | 6.74% | -14.8% |
| HZNP | Buy | HORIZON THERAPEUTICS PUB L | $54,349,173 | +149.9% | 477,585 | +35.9% | 6.38% | +120.1% |
| LEGN | Sell | LEGEND BIOTECH CORPsponsored ads | $52,659,110 | +19.9% | 1,054,870 | -2.0% | 6.18% | +5.5% |
| VRDN | Buy | VIRIDIAN THERAPEUTICS INC | $51,151,588 | +52.4% | 1,751,167 | +7.0% | 6.00% | +34.2% |
| SNDX | Buy | SYNDAX PHARMACEUTICALS INC | $49,742,330 | +90.8% | 1,954,512 | +80.1% | 5.84% | +68.0% |
| IMCR | Buy | IMMUNOCORE HLDGS PLCads | $48,961,780 | +34.9% | 857,925 | +11.0% | 5.75% | +18.8% |
| ASND | Sell | ASCENDIS PHARMA A/Ssponsored adr | $43,088,441 | -16.1% | 352,808 | -29.1% | 5.06% | -26.1% |
| VOR | Buy | VOR BIOPHARMA INC | $42,844,786 | +531.8% | 6,442,825 | +278.2% | 5.03% | +456.3% |
| UTHR | Buy | UNITED THERAPEUTICS CORP DEL | $41,405,376 | +40.7% | 148,892 | +5.9% | 4.86% | +23.9% |
| SGEN | New | SEAGEN INC | $36,790,871 | – | 286,288 | +100.0% | 4.32% | – |
| BCYC | Buy | BICYCLE THERAPEUTICS PLCsponsored ads | $36,505,088 | +35.4% | 1,233,280 | +6.4% | 4.28% | +19.3% |
| ARGX | Sell | ARGENX SEsponsored adr | $33,926,499 | +6.4% | 89,556 | -0.8% | 3.98% | -6.3% |
| AKRO | Sell | AKERO THERAPEUTICS INC | $33,129,011 | +16.8% | 604,544 | -27.4% | 3.89% | +2.8% |
| New | ARCELLX INC | $27,327,489 | – | 882,101 | +100.0% | 3.21% | – | |
| KRTX | New | KARUNA THERAPEUTICS INC | $20,870,265 | – | 106,210 | +100.0% | 2.45% | – |
| ARVN | Buy | ARVINAS INC | $20,512,282 | +62.5% | 599,599 | +111.3% | 2.41% | +43.1% |
| ALPN | Buy | ALPINE IMMUNE SCIENCES INC | $17,034,610 | +6.8% | 2,317,634 | +4.6% | 2.00% | -5.9% |
| CRNX | Buy | CRINETICS PHARMACEUTICALS IN | $16,288,922 | +59.7% | 890,105 | +71.4% | 1.91% | +40.7% |
| ZLAB | New | ZAI LAB LTDadr | $15,818,912 | – | 515,274 | +100.0% | 1.86% | – |
| PSTX | Buy | POSEIDA THERAPEUTICS INC | $12,904,525 | +76.6% | 2,434,816 | +17.6% | 1.52% | +55.5% |
| PRTA | Sell | PROTHENA CORP PLC | $4,518,750 | -68.4% | 75,000 | -68.2% | 0.53% | -72.2% |
| MIST | Exit | MILESTONE PHARMACEUTICALS IN | $0 | – | -634,211 | -100.0% | -0.78% | – |
| TGTX | Exit | TG THERAPEUTICS INC | $0 | – | -1,505,479 | -100.0% | -1.19% | – |
| OYST | Exit | OYSTER PT PHARMA INC | $0 | – | -1,648,316 | -100.0% | -1.24% | – |
| GTHX | Exit | G1 THERAPEUTICS INC | $0 | – | -884,574 | -100.0% | -1.47% | – |
| MRUS | Exit | MERUS N V | $0 | – | -564,214 | -100.0% | -1.51% | – |
| ESPR | Exit | ESPERION THERAPEUTICS INC NE | $0 | – | -1,719,831 | -100.0% | -1.54% | – |
| AXSM | Exit | AXSOME THERAPEUTICS INC | $0 | – | -520,080 | -100.0% | -3.09% | – |
| BIIB | Exit | BIOGEN INCcall | $0 | – | -150,000 | -100.0% | -5.34% | – |
| GBT | Exit | GLOBAL BLOOD THERAPEUTICS IN | $0 | – | -1,175,879 | -100.0% | -10.68% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2023-02-14
Signatures
The EDGAR filing(s) were signed by:
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| LEGEND BIOTECH CORP | 8 | Q3 2023 | 10.7% |
| MIRATI THERAPEUTICS INC | 8 | Q3 2023 | 10.9% |
| VIRIDIAN THERAPEUTICS INC | 8 | Q3 2023 | 6.8% |
| IMMUNOCORE HLDGS PLC | 8 | Q3 2023 | 5.9% |
| SYNDAX PHARMACEUTICALS INC | 8 | Q3 2023 | 5.8% |
| VOR BIOPHARMA INC | 8 | Q3 2023 | 5.0% |
| INCYTE CORP | 7 | Q3 2023 | 8.6% |
| ARGENX SE | 7 | Q3 2023 | 8.7% |
| UNITED THERAPEUTICS CORP DEL | 7 | Q3 2023 | 7.7% |
| ALPINE IMMUNE SCIENCES INC | 7 | Q3 2023 | 2.1% |
View Paradigm Biocapital Advisors LP's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| SC 13G | 2024-04-08 |
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
View Paradigm Biocapital Advisors LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.